Actinogen Medical (ASX:ACW) has announced the appointment of Andrew Udell, a US-based executive, as its chief commercial officer, reporting to CEO Dr Steven Gourlay.
Actinogen Medical is developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. It is currently developing its lead compound, Xanamem, as a potential new therapy for Alzheimer’s disease and depression.
Mr Udell is a commercial leader who has successfully taken biotechnology companies from the clinic through market planning, commercial readiness, and full commercial integration.
Most recently, Mr Udell was President of North America at Calliditas Therapeutics, taking this Swedish company through phase 3 trials, market readiness and a successful US product launch. Mr Udell was previously the Vice President of Commercial for North America for Neuroderm before its acquisition by Mitsubishi Tanabe Pharma. Mr Udell has significant experience working in depression, Parkinson’s Disease, and other large central nervous system (CNS) markets.
CEO Dr Steven Gourlay said, “Actinogen is delighted to have Andy Udell strengthen our executive leadership with his extensive commercial experience as our clinical trial programs advance towards marketing approvals. Andy has comprehensive knowledge, skills and acumen in readying and bringing CNS drugs to market and we welcome him to the executive leadership team.”